Patents by Inventor Surender Khurana

Surender Khurana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210208160
    Abstract: Methods of identifying a subject with a Filovirus infection are provided herein. In some embodiments, the method comprises contacting a biological sample containing antibodies from the subject with one or more peptides comprising amino acid sequences of selected Filovirus epitopes, detecting the presence or absence of an immune complex of antibodies from the biological sample with the one or more peptides; and wherein the presence of the immune complex identifies the subject as having Filovirus infection and the absence of the immune complex identifies the subject as not having Filovirus infection. Further provided are isolated peptides for use in such methods, as well as a solid support linked to one or more of the disclosed peptides.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 8, 2021
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Surender Khurana
  • Publication number: 20200345829
    Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 5, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Surender Khurana, Hana Golding
  • Publication number: 20200348299
    Abstract: Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.
    Type: Application
    Filed: March 26, 2020
    Publication date: November 5, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Surender Khurana
  • Publication number: 20200299335
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.
    Type: Application
    Filed: November 27, 2018
    Publication date: September 24, 2020
    Applicants: and Human Services
    Inventor: Surender Khurana
  • Patent number: 10744193
    Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Surender Khurana, Hana Golding
  • Publication number: 20200054734
    Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 20, 2020
    Applicant: The United States of America, as represented by the Secretary, Department Health and Human Service
    Inventor: Surender Khurana
  • Patent number: 10377798
    Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: August 13, 2019
    Assignee: The United States of America, as rerpresented by the Secretary, Department of Health and Human Services
    Inventors: Surender Khurana, Hana Golding
  • Publication number: 20180110850
    Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.
    Type: Application
    Filed: February 18, 2016
    Publication date: April 26, 2018
    Applicant: The United States of America, as Represented by the Secretary, Dept. of Health and Human Service
    Inventors: Surender Khurana, Hana Golding
  • Patent number: 9896484
    Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: February 20, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Surender Khurana, Hana Golding
  • Publication number: 20160368949
    Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.
    Type: Application
    Filed: October 19, 2015
    Publication date: December 22, 2016
    Inventors: Hana Golding, Surender Khurana
  • Publication number: 20160304565
    Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered) for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.
    Type: Application
    Filed: December 2, 2014
    Publication date: October 20, 2016
    Inventors: Surender KHURANA, Hana GOLDING
  • Patent number: 9163068
    Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: October 20, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer
    Inventors: Surender Khurana, Hana Golding
  • Patent number: 9121855
    Abstract: This invention concerns methods for detecting the presence of an anti-HIV-1 antibody in a biological sample, the method comprising conducting an immunoassay comprising: (a) contacting the biological sample with at least one epitope that is recognized by the anti-HIV-1 antibody, wherein the contacting being under conditions sufficient to permit the anti-HIV-1 antibody if present in the sample to bind to the epitope and form an epitope-anti-HIV-1 antibody complex; (b) contacting the formed epitope-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, the contacting being under conditions sufficient to permit the anti- HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed epitope-anti-HIV-1 antibody complex and form an extended complex; and (c) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentration of the formed extended complex; the epitope being present on a peptide comprising SEQ ID N
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: September 1, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 8980546
    Abstract: This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: March 17, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 8778847
    Abstract: Peptides and polypeptides that elicit immunogenic responses in a mammal; especially neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7 are disclosed Immunogenic compositions including these peptides, and polypeptides are also provided. Compositions including these peptides and polypeptides with or without adjuvants are disclosed. Nucleic acids and expression cassettes encoding these peptides and polypeptides are also disclosed. Methods of inhibiting infection by influenza, with or without cell entry, are also disclosed using these peptides and polypeptides.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 8722324
    Abstract: This invention relates to compositions and methods or the detection of human immunodeficiency virus-1 (HIV-1) infection by conducting an immunoassay comprising the steps of: (a) contacting a biological sample containing HIV-1 antibody with a peptide, having an epitope, of one or more of SEQ ID 49-56 to form a peptide-anti-HIV-1 antibody complex; (b) contacting the formed complex with an anti-HIV-1 antibody binding molecule to permit the anti-HIV-1 antibody binding molecule to bind to the anti-HIV-1 antibody of the formed peptide-anti-HIV-1 antibody complex and form an extended complex that is immobilized on a solid support; (c) removing unbound anti-HIV-1 antibody and anti-HIV-1 antibody binding molecule from the extended complex; and (d) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: May 13, 2014
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Publication number: 20130143202
    Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.
    Type: Application
    Filed: December 23, 2010
    Publication date: June 6, 2013
    Applicant: The Government of the United States of America as represented by the Secretary, Department of Health
    Inventors: Hana Golding, Surender Khurana
  • Publication number: 20130137083
    Abstract: A combination of H5N1 influenza peptides that provide for H5N1 diagnosis with a high level of sensitivity and specificity is described.
    Type: Application
    Filed: April 14, 2011
    Publication date: May 30, 2013
    Applicants: The Goverment of the United States of Americaas Represented by the Secretary of the Department of Health and Human Services
    Inventors: Surender Khurana, Hana Golding
  • Publication number: 20120301504
    Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.
    Type: Application
    Filed: November 2, 2010
    Publication date: November 29, 2012
    Applicant: The Gov't of the USA As Represented by the Secreta ry of the Dept. of Health and Human Services, Nat
    Inventors: Surender Khurana, Hana Golding
  • Patent number: 8282926
    Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: October 9, 2012
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana